Structural Heart最新文献

{"title":"Aims & Scope","authors":"","doi":"10.1016/S2474-8706(24)00119-2","DOIUrl":"10.1016/S2474-8706(24)00119-2","url":null,"abstract":"","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 5","pages":"Article 100364"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870624001192/pdfft?md5=c1e4f0f2004f408fb0fd394edda3dad0&pid=1-s2.0-S2474870624001192-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142095428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Risk Score Facilitates Femoral Artery Access in Transcatheter Aortic Valve Implantation: Passage-Puncture Score","authors":"Mi Chen MD, PhD ,&nbsp;Jonathan Michel MD ,&nbsp;Barbara E. Stähli MD, MPH, MBA,&nbsp;Christian Templin MD, PhD,&nbsp;Philipp Jakob MD,&nbsp;Thomas S. Gilhofer MD,&nbsp;Felix C. Tanner MD,&nbsp;Albert Markus Kasel MD","doi":"10.1016/j.shj.2024.100331","DOIUrl":"10.1016/j.shj.2024.100331","url":null,"abstract":"<div><h3>Background</h3><p>Vascular complications remain high in transfemoral transcatheter aortic valve implantation (TAVI). Careful evaluation of the femoral arteries is important to select the optimal access site.</p></div><div><h3>Objectives</h3><p>This study sought to describe a novel risk score (the passage-puncture score) for transfemoral access using a single suture-based closure system.</p></div><div><h3>Methods</h3><p>The passage-puncture score consists of the evaluation of 1) passage feasibility of the ilio-femoral arteries (passage score) and 2) puncture site feasibility (puncture score) based on pre-TAVI computed tomography. All patients underwent fluoroscopy-guided arterial puncture and closure with a suture-based closure system. The primary endpoint was the rate of vascular complications in discharge, including minor and major vascular complications according to the definitions of the Third Valve Academic Research Consortium.</p></div><div><h3>Results</h3><p>From September 2020 to June 2021, transfemoral TAVI was performed in 98 of 99 patients. Passage score (right) was significantly higher in patients treated by left compared to those treated by right femoral access (3 vs. 1; <em>p</em> &lt;0.001). Puncture score was significantly different between patients undergoing mid-femoral as compared to nonmid-femoral puncture (0 vs. 3, <em>p</em> &lt;0.001). Minor vascular complications occurred in six (6%) patients.</p></div><div><h3>Conclusions</h3><p>The passage-puncture score is effective in defining the optimal access site for transfemoral TAVI. The systematic evaluation has the potential to further reduce access-site complications.</p></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 5","pages":"Article 100331"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870624000794/pdfft?md5=d5e9b0f690c46b2a630cde4086fc1664&pid=1-s2.0-S2474870624000794-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142095427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary Vein Systolic Flow Reversal and Outcomes in Patients From the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (COAPT) Trial","authors":"Chandrashekar Bohra MD ,&nbsp;Federico M. Asch MD ,&nbsp;Stamatios Lerakis MD ,&nbsp;Stephen H. Little MD ,&nbsp;Björn Redfors MD, PhD ,&nbsp;Zhipeng Zhou MA ,&nbsp;Yanru Li MS, MPH ,&nbsp;Neil J. Weissman MD ,&nbsp;Paul A. Grayburn MD ,&nbsp;Saibal Kar MD ,&nbsp;D. Scott Lim MD ,&nbsp;William T. Abraham MD ,&nbsp;JoAnn Lindenfeld MD ,&nbsp;Michael J. Mack MD ,&nbsp;Jeroen J. Bax MD, PhD ,&nbsp;Gregg W. Stone MD","doi":"10.1016/j.shj.2024.100333","DOIUrl":"10.1016/j.shj.2024.100333","url":null,"abstract":"<div><h3>Background</h3><p>The implications of pulmonary vein (PV) flow patterns in patients with heart failure (HF) and mitral regurgitation (MR) are uncertain. We examined PV flow patterns in the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (COAPT) trial (NCT01626079), in which patients with HF and moderate-to-severe or severe functional MR were randomized to transcatheter edge-to-edge repair (TEER) with the MitraClip device plus guideline-directed medical therapy (GDMT) vs. GDMT alone. We sought to evaluate the prognostic utility of baseline PV systolic flow reversal (PVSFR) in HF patients with severe MR and to determine whether the presence of PVSFR can discriminate patients most likely to benefit from TEER in COAPT trial patients.</p></div><div><h3>Methods</h3><p>Patients were categorized by the echocardiographic core laboratory-assessed baseline presence of PVSFR. Two-year outcomes were examined according to PVSFR and treatment.</p></div><div><h3>Results</h3><p>Baseline PV flow patterns were evaluable in 526/614(85.7%) patients, 48.9% of whom had PVSFR. Patients with PVSFR had more severe MR, reduced stroke volume and cardiac output, greater right ventricular dysfunction, and worse hemodynamics. By multivariable analysis, PVSFR was not an independent predictor of 2-year all-cause death, or heart failure hospitalization (HFH). The reductions in the 2-year rates of all-cause death and HFH with TEER compared with GDMT alone were similar in patients with and without PVSFR (P_interaction = 0.40 and 0.12, respectively). The effect of TEER on improving Kansas City Cardiomyopathy Questionnaire scores and 6-minute walk distance were also independent of PVSFR.</p></div><div><h3>Conclusions</h3><p>In the COAPT trial, PVSFR identified HF patients with severe MR and more advanced heart disease. Patients with and without PVSFR had consistent reductions in mortality, HFH, and improved quality-of-life and functional capacity after TEER.</p></div><div><h3>Clinical Trial Registration</h3><p><span><span>ClinicalTrial.gov</span><svg><path></path></svg></span> Identifier<span><span>NCT01626079</span><svg><path></path></svg></span>.</p></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 5","pages":"Article 100333"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870624000812/pdfft?md5=797d9be1e53dba2ab94537917306a130&pid=1-s2.0-S2474870624000812-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142095431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative Aortography Analysis of JenaValve’s Trilogy Transcatheter Aortic Valve Implantation System in Patients With Aortic Regurgitation or Stenosis","authors":"Tsung-Ying Tsai MD ,&nbsp;Hesham Elzomor MD ,&nbsp;Hendrik Wienemann MD ,&nbsp;Pruthvi Chenniganahosahalli Revaiah MD ,&nbsp;Ralph Stephan von Bardeleben MD, PhD ,&nbsp;Alexander Tamm MD ,&nbsp;Scot Garg MD, PhD ,&nbsp;Osama Soliman MD, PhD ,&nbsp;Yoshinobu Onuma MD, PhD ,&nbsp;Hans R. Figulla MD, PhD ,&nbsp;Matti Adam MD ,&nbsp;Tanja Rudolph MD ,&nbsp;Patrick W. Serruys MD, PhD","doi":"10.1016/j.shj.2024.100346","DOIUrl":"10.1016/j.shj.2024.100346","url":null,"abstract":"<div><h3>Background</h3><p>JenaValve’s Trilogy transcatheter heart valve (THV) (JenaValve Inc, Irvine, CA) is the only <em>conformité européenne</em>-marked THV system for the treatment of aortic regurgitation (AR) or aortic stenosis (AS). However, its efficacy has not been quantitatively investigated pre- and post-implantation using video-densitometric analysis.</p></div><div><h3>Methods</h3><p>Using the CAAS-A-Valve 2.1.2 software (Pie Medical Imaging, Maastricht, the Netherlands), an independent core lab retrospectively analyzed the aortograms of 88 consecutive patients (68 severe AR; 20 severe AS) receiving the JenaValve THV in three European centers. Video-densitometric AR was categorized by the regurgitant fraction (RF) as none/trace AR (RF ≤ 6%), mild (6% &lt; RF ≤ 17%), and moderate/severe AR (RF &gt; 17%).</p></div><div><h3>Results</h3><p>Pre- and post-THV aortograms were analyzable in 17 (22.4%) and 47 (54.0%) patients, respectively. The main reasons preventing analysis were the descending aorta overlap of the outflow tract (30%) and insufficient frame count (6%). The median RF pre- and post-THV implant was 31.0% (interquartile range 21.5-38.6%) and 5.0% (interquartile range 1.0-7.0%, <em>p</em> &lt; 0.001), respectively. The post-THV incidence of none/trace AR was 72.3%, and of mild AR, 27.7%, with no cases of moderate/severe AR. Video-densitometry analysis of the 12 AR cases with paired pre- and post-THV showed a reduction in the RF of 21.8% ± 8.1%.</p></div><div><h3>Conclusions</h3><p>Quantitative aortography confirms the low rates of AR and the large reduction in RF following the implantation of Jenavalve’s Trilogy THV, irrespective of implant indication. However, these limited data need corroborating in prospective studies using standardized acquisition protocols.</p></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 5","pages":"Article 100346"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870624001015/pdfft?md5=59d38430975889acd7ccd93231942767&pid=1-s2.0-S2474870624001015-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141845159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First Case of the Treatment of Massive Tricuspid Regurgitation With the CroíValve DUO Coaptation Valve in a Patient With a Right Ventricular Pacemaker Lead","authors":"Ewa Peszek-Przybyła MD, PhD ,&nbsp;Marek Jędrzejek MD, PhD ,&nbsp;Grzegorz Smolka MD, PhD ,&nbsp;Martin J. Quinn MD, PhD ,&nbsp;Piotr Pysz MD, PhD ,&nbsp;Wojtek Wojakowski MD, PhD","doi":"10.1016/j.shj.2024.100329","DOIUrl":"10.1016/j.shj.2024.100329","url":null,"abstract":"<div><h3>Background</h3><p>Tricuspid regurgitation (TR) is a common valvular disorder with limited treatment options. It occurs when tricuspid leaflet closure is prevented by dilation of the right heart or in patients with cardiac implantable rhythm devices when the transvalvular lead impedes proper closure of the valve. The management of these patients can be complicated. The removal of the lead often does not improve the TR, and surgical repair is usually not possible because of comorbidities. A number of percutaneous TR repair and replacement devices have been developed; however, the presence of the right ventricular lead can prevent the delivery of these devices, or the device may displace the pacemaker lead. We report the first implant of the CroíValve DUO Transcatheter Tricuspid Coaptation Valve System (Dublin, Ireland) in a patient with massive TR and a right ventricular lead.</p></div><div><h3>Methods</h3><p>The patient was not a fit for surgical treatment and underwent transcatheter treatment following compassionate use approval. The procedure was performed under general anesthetic with echo and X-ray guidance. The device was delivered through the right internal jugular vein.</p></div><div><h3>Results</h3><p>The device was implanted successfully, and the TR was reduced from massive to mild at 90-day follow-up. The patient’s quality of life improved significantly with an improvement in 6-minute walk test (382 m at baseline to 467 m at follow-up), the New York Heart Association classification (III at baseline to I at follow-up), and the Kansas City Cardiomyopathy Questionnaire (baseline score 43 increased to 60). The efficacy and clinical improvement have been stable over the past 90 days of follow-up, and the patient has not suffered any adverse events.</p></div><div><h3>Conclusions</h3><p>This is the first implantation of the CroíValve DUO Coaptation Valve System in a patient with a pacemaker lead. In these patients, this device may offer advantages over other current transcatheter approaches.</p></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 5","pages":"Article 100329"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870624000770/pdfft?md5=28651adb975d7b4feecdbf3ca27f7025&pid=1-s2.0-S2474870624000770-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142095641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moderate Aortic Stenosis—Advanced Imaging, Risk Assessment, and Treatment Strategies","authors":"","doi":"10.1016/j.shj.2023.100279","DOIUrl":"10.1016/j.shj.2023.100279","url":null,"abstract":"<div><p>Moderate aortic stenosis is increasingly recognized as a disease entity with poor prognosis. Diagnosis of moderate aortic stenosis may be complemented by laboratory tests and advanced imaging techniques focused at detecting signs of cardiac damage such as increase of cardiac enzymes (N-terminal pro-B-type Natriuretic Peptide, troponin), left ventricular remodeling (hypertrophy, reduced left ventricular ejection fraction), or myocardial fibrosis. Therapy should include guideline-directed optimal medical therapy for heart failure. Patients with signs of cardiac damage may benefit from early intervention, which is the focus of several ongoing randomized controlled trials. As yet, no evidence-based therapy exists to halt the progression of aortic valve calcification.</p></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 5","pages":"Article 100279"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870623002300/pdfft?md5=3a96ecae98a1bcfd2fb3979087e8f9ef&pid=1-s2.0-S2474870623002300-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139825807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Transcatheter Aortic Valve Replacement-Conduction Study: The Value of the His-Ventricular Interval in Risk Stratification for Post-TAVR Atrioventricular-Block","authors":"","doi":"10.1016/j.shj.2024.100296","DOIUrl":"10.1016/j.shj.2024.100296","url":null,"abstract":"<div><h3>Background</h3><p>There is no clear consensus regarding the optimal risk stratification of high-degree atrioventricular block (HDAVB) after transcatheter aortic valve replacement (TAVR).</p></div><div><h3>Methods</h3><p>This prospective study sought to determine the utility of the pre- and post-TAVR His-ventricular (HV) interval in the risk stratification of post-TAVR HDAVB. One hundred twenty-one patients underwent an electrophysiology study before and after TAVR. The primary outcome was HDAVB requiring pacemaker implantation within 30 days post-TAVR. A separate retrospective cohort was analyzed to determine the postoperative interval at which the risk of HDAVB is reduced to &lt;5%.</p></div><div><h3>Results</h3><p>HDAVB occurred in 12 (10%) patients. Baseline right bundle branch block (RBBB) (odds ratio [OR]: 13.6), implant depth &gt;4 mm (OR: 3.9), use of mechanically- or self-expanding valves (OR: 6.3), and post-TAVR HV &gt; 65 ​ms (OR: 4.9) were associated with increased risk of HDAVB, whereas PR intervals and pre-TAVR HV were not. In patients without baseline RBBB or new persistent left bundle branch block (LBBB), not one patient with post-TAVR HV &lt; 65 ​ms developed HDAVB. In the separate retrospective cohort (N = 1049), the risk of HDAVB is reduced (&lt;5%) on postoperative days 4 and 3 in patients with pre-TAVR RBBB and post-TAVR persistent LBBB, respectively.</p></div><div><h3>Conclusions</h3><p>Baseline RBBB, new persistent LBBB, implant depth &gt;4 mm, and a post-TAVR HV ≥ 65 ​ms were associated with a higher risk of post-TAVR HDAVB, whereas an HV ≤ 65 ​ms was associated with a lower risk. The pre-TAVR HV was not associated with our outcome, and the delta HV did not have practical incremental prognostic value. Among those without pre-TAVR RBBB or post-TAVR persistent LBBB, no patients with post-TAVR HV &lt; 65 ​ms developed HDAVB.</p></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 5","pages":"Article 100296"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870624000277/pdfft?md5=580d9deba1c9f66932a432b36eb32ecc&pid=1-s2.0-S2474870624000277-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140281783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing the Occupational Risk of Radiation Exposure in the Evolving Field of Interventional Echocardiography","authors":"Philipp Lauten MD,&nbsp;Harald Lapp MD,&nbsp;Björn Goebel MD","doi":"10.1016/j.shj.2024.100328","DOIUrl":"10.1016/j.shj.2024.100328","url":null,"abstract":"<div><p>Interventional echocardiography (IE) is a relatively new subspecialty in the field of cardiology that has rapidly evolved to occupy a critical role in the treatment of structural heart disease. Despite this, clear competency guidelines are only now being issued, and, of pressing importance, the health risks associated with the profession, particularly occupational radiation exposure, still need to be recognized and appropriately addressed for both specialists and trainees in IE as well as for supporting sonographers. This review will briefly discuss the extensive training interventional echocardiographers need in advanced imaging modalities and will then present standard measures as well as possible innovative devices that can be implemented to reduce ionizing radiation exposure for those working in the field of IE.</p></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 5","pages":"Article 100328"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870624000769/pdfft?md5=f6d507c9fd4090b897ed4ab35587badc&pid=1-s2.0-S2474870624000769-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142095430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous Closure of a Left Ventricular Pseudoaneurysm","authors":"","doi":"10.1016/j.shj.2024.100320","DOIUrl":"10.1016/j.shj.2024.100320","url":null,"abstract":"","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 4","pages":"Article 100320"},"PeriodicalIF":1.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S247487062400068X/pdfft?md5=a658a61b0f4fa273afc902f00468a008&pid=1-s2.0-S247487062400068X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141411416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thirty-Day High-Grade Aortic Valve Block Post-Transcatheter Aortic Valve Replacement in Patients Discharged on Heart Rhythm Monitor","authors":"","doi":"10.1016/j.shj.2024.100317","DOIUrl":"10.1016/j.shj.2024.100317","url":null,"abstract":"<div><h3>Background</h3><p>Conduction disease is an important and common complication post-transcatheter aortic valve replacement (TAVR). Previously, we developed a conduction disease risk stratification and management protocol post-TAVR. This study aims to evaluate high-grade aortic valve block (HAVB) incidence and risk factors in a large cohort undergoing ambulatory cardiac monitoring post-TAVR according to conduction risk grouping.</p></div><div><h3>Methods</h3><p>This single-center, retrospective study evaluated all patients discharged on ambulatory cardiac monitoring between 2016 and 2021 and stratified them into 3 groups based on electrocardiogram predictors of HAVB risk (group 1 [low], group 2 [intermediate], and group 3 [high]). HAVB was defined as ≥2 consecutive nonconducted P waves in sinus rhythm or bradycardia &lt;50 beats/minute with a fixed rate for atrial fibrillation/flutter. Descriptive statistics were used to show the incidence and timeline, while logistic regression was utilized to evaluate predictors of HAVB.</p></div><div><h3>Results</h3><p>Five hundred twenty-eight patients were included (median age 80 years [74-85]; 43.8% female). Forty-one patients (7.8%) developed HAVB during ambulatory monitoring (68% were asymptomatic). Over a median follow-up of 2 years (1.3-2.7), the overall mortality rate was 15.0% (30-day mortality rate of 0.57%, n = 3). Risk factors for HAVB were male sex (odds ratio [OR] = 2.46, <em>p</em> = 0.02, 95% CI = 1.21-5.43), baseline right bundle branch block (OR = 2.80, <em>p</em> = 0.01, 95% CI = 1.17-6.19), and post-TAVR QRS &gt;150 ​ms (OR = 2.16, <em>p</em> = 0.03, 95% CI = 1.01-4.40). The negative predictive value for patients in groups 1 and 2 for 30-day HAVB was 95.0 and 93.8%, respectively.</p></div><div><h3>Conclusions</h3><p>The risk of 30-day HAVB post-TAVR on ambulatory monitoring post-TAVR varies according to post-TAVR electrocardiogram findings, and a 3-group algorithm effectively identifies groups with a low negative predictive value for HAVB.</p></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 4","pages":"Article 100317"},"PeriodicalIF":1.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870624000654/pdfft?md5=a068e70f14d7024f3f3d40417d2d999f&pid=1-s2.0-S2474870624000654-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141140316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}